- Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis
- Cryptosporidiosis is the second leading cause of infectious diarrhea in children
- Private companies, governments, non-governmental organizations, academia, and other stakeholders need to work together to create sustainable solutions for global health issues.
Basel, February 14, 2018 -Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis' drug candidate KDU731 for the treatment of cryptosporidiosis. Diarrheal diseases are one of the leading causes of childhood mortality globally, resulting in approximately 525,000 deaths each year and cryptosporidiosis is the second leading cause of infectious diarrhea in children under 2 years of age-. "There is an urgent medical need for new and effective therapeutics for cryptosporidiosis, particularly in vulnerable populations" said Dr. Paul Kelly University of Zambia School of Medicine and Tropical Gastroenterology at Barts & The London.
KDU731 is a Cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase) inhibitor, which has been shown to effectively treat Cryptosporidium infection in preclinical models and is currently undergoing safety studies prior to the initiation of clinical trials. Under the terms of the agreement, the Bill & Melinda Gates Foundation will provide $6.5 million to support the development of this drug candidate for the treatment of children by the Novartis Institute for Tropical Diseases (NITD).
"We are committed to the fight against cryptosporidiosis and other infectious and neglected tropical diseases and are proud to work closely with the Bill & Melinda Gates Foundation and other partners in this effort," said Thierry Diagana, Head of NITD. "Today`s global health issues cannot be solved by one organization alone. Private companies, governments, non-governmental organizations, academia, and other stakeholders need to work together to create sustainable solutions."
NITD is a Novartis research institute dedicated solely to the discovery and development of new medicines to treat malaria, cryptosporidiosis, and three major kinetoplastid diseases - human African trypanosomiasis (sleeping sickness), chagas disease and leishmaniasis.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]
 Kotloff, KL et al., "Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multisite Study, GEMS): a prospective, case-control Study." Lancet 2013 Jul 20; 382 (9888): 209-22
 Manjunatha, UH et al., "A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis" Nature 2017 June 14; 546 (7658): 376-80
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: [email protected]
| Eric Althoff |
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
| Sandra Schlüchter |
Novartis Institutes for Biomedical Research
+41 61 696 6806 (direct)
+41 79 826 0196 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]
|Samir Shah||+41 61 324 7944||Richard Pulik||+1 212 830 2448|
|Pierre-Michel Bringer||+41 61 324 1065||Cory Twining||+1 212 830 2417|
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|